T. Rowe Price Associates’s X4 Pharmaceuticals XFOR Stock Holding History

T. Rowe Price Associates’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,767	Closed	-$20K	–	3159
2025 Q1	$20K	Buy	2,767 +900	+48%	+$12.4K	﹤0.01%	3005
2024 Q4	$41K	Hold	1,867	–	–	﹤0.01%	2962
2024 Q3	$38K	Buy	1,867 +193	+12%	+$4.03K	﹤0.01%	2960
2024 Q2	$30K	Buy	1,674 +364	+28%	+$11.9K	﹤0.01%	2896
2024 Q1	$55K	Buy	1,310 +417	+47%	+$11.6K	﹤0.01%	2863
2023 Q4	$23K	Hold	893	–	–	﹤0.01%	2867
2023 Q3	$30K	Buy	893 +59	+7%	+$2.57K	﹤0.01%	2832
2023 Q2	$49K	Buy	+834	New	+$42.9K	﹤0.01%	2804
2020 Q2	–	Sell	-5,107	Closed	-$1.53M	–	2542
2020 Q1	$1.53M	Buy	+5,107	New	+$1.45M	﹤0.01%	1567

Other funds holding XFOR

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates's XFOR Position: Q2 2025 in Review

T. Rowe Price Associates sold out of X4 Pharmaceuticals (XFOR) in Q2 2025, closing a stake of 2,767 shares — an estimated $20K sold.

T. Rowe Price Associates first reported a position in XFOR in Q1 2020 and held it in 9 quarters. The position peaked at $1.53M in Q1 2020. 51 funds tracked by Wall St. Rank hold XFOR as of Q2 2025.

T. Rowe Price Associates reported no remaining X4 Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
T. Rowe Price Associates sold 2,767 X4 Pharmaceuticals shares in Q2 2025, an estimated $20K.
T. Rowe Price Associates first reported a position in X4 Pharmaceuticals in Q1 2020 and held it in 9 quarters.
T. Rowe Price Associates's X4 Pharmaceuticals position peaked at $1.53M in Q1 2020.
51 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.